Alyson Ross

Appearances

CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. TWO YEAR RESULTS OF THE STRIDENT RANDOMIZED CONTROLLED TRIAL.
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Speakers
Julien Schulberg
Amy Hamilton
Bronte Holt
Grace Lovett
Tom Sutherland
Alyson Ross
Sara Vogrin
Presenters
Emily Wright
Michael Kamm
PHAMRACOKINETICS OF VEDOLIZUMAB AND USTEKINUMAB IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE AND THEIR INFANTS EXPOSED IN-UTERO
Date
May 8, 2023
BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…
Speakers
Ralley Prentice
Emma Flanagan
Peter Gibson
Sam Rosella
Ourania Rosella
Rimma Goldberg
Lani Prideaux
Katerina Kiburg
Alyson Ross
Megan Burns
Presenters
Emily Wright
Sally Bell